Skip to main content
Premium Trial:

Request an Annual Quote

Cancer AI Startup Nucleai Raises $6.5M in Series A Financing

NEW YORK – Nucleai, a startup maker of a technology platform for precision oncology research and clinical decision support, said Tuesday that it has raised $6.5 million in the initial stage of a Series A funding round.

Swiss biopharmaceutical company Debiopharm led the investment, with participation from Vertex Ventures and Grove Ventures. As part of this investment, Debiopharm will collaborate with Nucleai on efforts to accelerate the discovery of biomarkers for oncology drug response.

Nucleai, based in Tel Aviv, Israel, relies on artificial intelligence to analyze large datasets of tissue images to model spatial characteristics of tumors and each patient's immune system to help predict patient response to various cancer therapies. The technology combines "computer vision" and machine learning, the company said.

"The battle between the tumor and the immune cells is clearly visible by inspecting the pathology slide, just like a satellite image of a battlefield. Our AI platform analyzes the hundreds of thousands of cells in a slide, examines the interplay between the tumor and the immune system and matches the right patient to the right drug based on these characteristics," Nucleai CEO Avi Veidman said in a statement.

"Our team is thrilled to embark on this adventure to develop and further understand the extent to which AI can help pathologists and oncologists become more precise in both diagnosis and prediction," added Tanja Dowe, CEO of the Debiopharm Innovation Fund. "We recognize the huge impact that Nucleai's AI-powered platform could have on clinical research for pharmaceutical treatments."

Nucleai closed a $5 million seed round in 2018. 

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.